| 8-OHdG | 8-hydroxy-2′-deoxyguanosine |
| acNPs | Acid-activated biodegradable nanoparticles |
| ALT/AST | Alanine/aspartate aminotransferase |
| AMLN | Amylin liver NASH diet |
| APAP | Acetaminophen |
| Au | Gold (nanoparticles) |
| BELNs | Blueberry-derived exosome-like nanoparticles |
| BMI | Body mass index |
| Cap-LNPs | Capsaicin-lignin nanoparticles |
| CeO2 | Cerium oxide |
| CCl4 | Carbon tetrachloride |
| DAMPS | Damage-associated molecular patterns |
| CDD | Choline-deficient diet |
| CD-HFD | Choline-deficient high-fat diet |
| CMNs | Cell-membrane nano-particles |
| CK | Compound K ( |
| DBZ | Dibenzazepine (PEGylated bilirubin NPs) |
| DSS | Dextran sulfate sodium |
| EGF | Epidermal growth factor |
| Et (chronic) | Chronic ethanol exposure |
| ER stress | Endoplasmic reticulum stress |
| EASD | European Association for the Study of Diabetes |
| EASL | European Association for the Study of the Liver |
| EASO | European Association for the Study of Obesity |
| ECM | Extracellular matrix |
| FA | Fatty acids |
| FFA | Free fatty acids |
| FXR | Farnesoid X receptor; |
| GalNAc | N-acetylgalactosamine |
| GLP-1 | Glucagon-like peptide-1 |
| GSH | Glutathione |
| HCC | Hepatocellular carcinoma |
| H-VLNs | Honey vesicle-like nanoparticles |
| Hep@PGEA | Hepatocyte-targeted poly(glycidyl methacrylate-ethanolamine) vector |
| HFD | High-fat diet |
| HFF | High-fat/high-fructose diet |
| HFHF | High-fat/high-fructose diet |
| HFCMCD | High-fat/high-cholesterol/methionine- and choline-deficient diet |
| HGF | Hepatocyte growth factor |
| HDL | High-density lipoprotein |
| HMGB1 | High mobility group box-1 |
| HSC | Hepatic stellate cell |
| IL-22 | Interleukin-22 |
| IR | Insulin resistance |
| MASLD | Metabolic dysfunction-associated steatotic liver disease |
| MASH | Metabolic dysfunction-associated steatohepatitis |
| mRNA-LNP | Messenger RNA–lipid nanoparticle |
| MSNs | Mesoporous silica nanoparticles |
| NASH | Non-alcoholic steatohepatitis |
| NAFLD | Non-alcoholic fatty liver disease |
| NanoCys | PEG–poly(cysteine) nanoparticles |
| NaYF4 | Sodium yttrium fluoride |
| NM-FGF19 | Non-mitogenic fibroblast growth factor 19 |
| LCS-SeNPs | Chitosan selenium nanoparticles |
| LDL | Low-density lipoprotein |
| OA | Oleic acid |
| PA | Palmitic acid |
| PI3K/AKT | Phosphoinositide-3-kinase/protein kinase B |
| PLGA | Poly(lactide-co-glycolide) |
| PNM | Platelet–neutrophil hybrid membrane |
| PNPLA3 I148M | Patatin-like phospholipase domain-containing protein 3 (I148M variant) |
| PPARα | Peroxisome proliferator-activated receptor-α |
| ROS | Reactive oxygen species |
| siRNA | Small interfering RNA |
| SCAR | Steatohepatitis-associated circRNA ATP5B Regulator |
| SGLT2 | Sodium–glucose cotransporter 2 |
| STZ | Streptozotocin |
| TEF | Naringin treatment in tissue-engineered fatty |
| TG | Triglycerides |
| TNF-α | Tumor necrosis factor-alpha |
| TiO2 | Titanium dioxide |